Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | FAAH | O00519 | 8/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1000814 | 1.00 | GAA (0.49) | GAAFAAHRECQLSMN1; SMN2HPGD | |
| SCHEMBL26031851 | 1.00 | GAA (0.49) | GAAFAAHRECQLSMN1; SMN2HPGD | |
| SCHEMBL17767844 | 0.88 | RECQL (0.47) | GAARECQLSMN1; SMN2HPGDHTT | |
| SCHEMBL337575 | 0.88 | SMN1; SMN2 (0.49) | FAAHSMN1; SMN2HPGDHTTKMT2A | |
| SCHEMBL4818636 | 0.88 | SMN1; SMN2 (0.49) | FAAHSMN1; SMN2HPGDHTTKMT2A | |
| SCHEMBL337176 | 0.88 | SMN1; SMN2 (0.49) | FAAHSMN1; SMN2HPGDHTTKMT2A | |
| SCHEMBL6048382 | 0.86 | FAAH (0.49) | FAAHSMN1; SMN2HPGDHTTKMT2A | |
| SCHEMBL6048378 | 0.86 | FAAH (0.49) | FAAHSMN1; SMN2HPGDHTTKMT2A | |
| SCHEMBL25542920 | 0.86 | CASP2 (0.50) | FAAHSMN1; SMN2HPGDHTTKMT2A | |
| SCHEMBL6048384 | 0.86 | FAAH (0.49) | FAAHSMN1; SMN2HPGDHTTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9333158-B2 | Spray base material including low-molecular gelator | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2016-05-10 | — | — | US | disclosed |
| US-9289496-B2 | Lipid dipeptide and gel | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2016-03-22 | — | — | US | disclosed |
| US-9265833-B2 | Lipid dipeptide and gel | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2016-02-23 | — | — | US | disclosed |
| US-20130267610-A1 | NOVEL LIPID DIPEPTIDE AND GEL | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2013-10-10 | — | — | US | disclosed |
| US-20130267609-A1 | NOVEL LIPID DIPEPTIDE AND GEL | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2013-10-10 | — | — | US | disclosed |
| US-20120035108-A1 | SPRAY BASE MATERIAL INCLUDING LOW-MOLECULAR GELATOR | KYUSHU UNIVERSITY (JP) | 2012-02-09 | — | — | US | disclosed |
| US-20110183913-A1 | NOVEL LIPID DIPEPTIDE AND GEL | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2011-07-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130267609-A1 | NOVEL LIPID DIPEPTIDE AND GEL | NGLY1, GGH, ARGLU1 | GAA 1929/4885FAAH 42/4885RECQL 2173/4885 |
| US-20110183913-A1 | NOVEL LIPID DIPEPTIDE AND GEL | NGLY1, ARGLU1, GGH | GAA 1860/4885FAAH 42/4885RECQL 1918/4885 |
| US-20130267610-A1 | NOVEL LIPID DIPEPTIDE AND GEL | NGLY1, GGH, ARGLU1 | GAA 1929/4885FAAH 42/4885RECQL 2173/4885 |
| US-20120035108-A1 | SPRAY BASE MATERIAL INCLUDING LOW-MOLECULAR GELATOR | CUTA, DSG1, STMN1 | GAA 2501/4885FAAH 480/4885RECQL 1024/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.